Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 202-208

  Warlick, Erica D ^a   Paulson, Kristjan ^b   Brazauskas, Ruta ^c   Zhong, Xiaobo ^c   Miller, Alan M ^d   Camitta, Bruce M ^e   George, Biju ^f   Savani, Bipin N ^g   Ustun, Celalettin ^a   Marks, David I ^h   Waller, Edmund K ⁱ   Baron, Frédéric ^j   Freytes, César O ^k   Socie, Gérard ^l   Akpek, Gorgun ^m   Schouten, Harry C ⁿ   Lazarus, Hillard M ^o   Horwitz, Edwin M ^p   Koreth, John ^q   Cahn, Jean Yves ^r   Bornhauser, Martin ^s   Seftel, Matthew ^b   Cairo, Mitchell S ^t   Laughlin, Mary J ^u   Sabloff, Mitchell ^v   Ringdén, Olle ^w   Gale, Robert Peter ^x   Kamble, Rammurti T ^y   Vij, Ravi ^z   Gergis, Usama ^aa   Mathews, Vikram ^g   Saber, Wael ^c   Chen, Yi Bin ^ab   Liesveld, Jane L ^ac   Cutler, Corey S ^q   Ghobadi, Armin ^ad   Uy, Geoffrey L ^x   Eapen, Mary ^c   Weisdorf, Daniel J ^a   Litzow, Mark R ^ae   more..

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e Children's Hospital of Wisconsin   (United States)

^f CHRISTIAN MEDICAL COLLEGE   (India)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

ⁱ EMORY UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^l SAINT LOUIS HOSPITAL   (France)

^m Banner MD Anderson Cancer Center   (United States)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^p CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

^s UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^t NEW YORK MEDICAL COLLEGE   (United States)

^u UNIVERSITY OF VIRGINIA   (United States)

^v OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^w KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^x IMPERIAL COLLEGE LONDON   (United Kingdom)

^y CENTER FOR CELL AND GENE THERAPY   (United States)

^z WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aa WEILL CORNELL MEDICAL COLLEGE   (United States)

^ab MASSACHUSETTS GENERAL HOSPITAL   (United States)

^ac STRONG MEMORIAL HOSPITAL   (United States)

^ad UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ae MAYO CLINIC ROCHESTER   (United States)

more..

Author keywords

AML; Cytarabine consolidation; RIC

Indexed keywords

ALEMTUZUMAB; AMSACRINE; ANTHRACYCLINE; BUSULFAN; CARMUSTINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ENOCITABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB; MELPHALAN; MITOXANTRONE; THIOTEPA; THYMOCYTE ANTIBODY; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPHIL ENGRAFTMENT; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT SELECTION; POSTREMISSION THERAPY; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; WHOLE BODY RADIATION;

AML; CYTARABINE CONSOLIDATION; RIC;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84893149821     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.023     Document Type: Article

References (25)

1. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. NEngl J Med 1994, 331:896-903.
2. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
3. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united kingdom medical research council trials. Blood 2010, 116:354-365.
4. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
5. Tallman M.S., Rowlings P.A., Milone G., et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000, 96:1254-1258.
6. Cahn J., Labopin M., Sierra J., et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:308-314.
7. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
8. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047-1055.
9. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
10. Martino R., Valcarcel D., Brunet S., et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008, 41:33-38.
11. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
12. Bornhauser M., Kienast J., Trenschel R., et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial. Lancet Oncol 2012, 13:1035-1044.
13. Ringden O., Erkers T., Aschan J., et al. Aprospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukemia undergoing allogeneic haematopoietic stem cell transplantation. JIntern Med 2013, 274:153-162.
14. McCormack S.E., Cao Q., Oran B., et al. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 2011, 35:757-761.
15. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
16. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009, 15:367-369.
17. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
18. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000, 111:18-29.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
20. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria. Blood 2011, 118:4242-4249.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
22. Farag S., Ruppart A., Mrozek K., et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study. JClin Oncol 2005, 23:482-493.
23. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013, 121:26-28.
24. Buckley S.A., Appelbaum F.R., Walter R.B. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 2012, 48:630-641.
25. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.